Xilio Therapeutics Ownership | Who Owns Xilio Therapeutics?


OverviewRevenueFinancialsChart

Xilio Therapeutics Ownership Summary


Xilio Therapeutics is owned by 22.86% institutional investors, 45.12% insiders, and 32.01% retail investors. Gilead sciences is the largest institutional shareholder, holding 9.44% of XLO shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.40% of its assets in Xilio Therapeutics shares.

XLO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockXilio Therapeutics22.86%45.12%32.01%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Gilead sciences9.11M9.44%$7.67M
Rivervest venture management1.44M5.16%$1.37M
Bain capital life sciences investors4.57M4.74%$3.85M
Merck1.48M1.54%$1.25M
Takeda pharmaceutical1.48M1.53%$1.24M
Vanguard group1.26M1.30%$1.06M
Morgan stanley961.92K1.00%$810.61K
Aju ib investment667.74K0.69%$595.56K
Fmr511.82K0.53%$431.31K
Geode capital management328.97K0.34%$277.26K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Rivervest venture management1.44M20.01%$1.37M
Takeda pharmaceutical1.48M7.59%$1.24M
Merck1.48M0.55%$1.25M
Aju ib investment667.74K0.52%$595.56K
Gilead sciences9.11M0.43%$7.67M
Bain capital life sciences investors4.57M0.26%$3.85M
Trustees of columbia university in the city of new york249.63K0.03%$210.44K
Two sigma securities32.13K0.00%$27.08K
Investors asset management of georgia inc /ga/ /adv10.00K0.00%$8.43K
Xtx topco76.05K0.00%$64.08K

Top Buyers

HolderShares% AssetsChange
State street163.89K-120.50K
Vanguard group1.26M-104.67K
Squarepoint ops328.79K0.00%93.34K
Susquehanna group, llp49.09K-49.09K
Xtx topco76.05K0.00%41.32K

Top Sellers

HolderShares% AssetsChange
Rock springs capital management lp---3.00M
Ghisallo capital management---1.33M
Atlas venture life science advisors---992.91K
Morgan stanley961.92K--482.41K
Ubs group13.65K--226.32K

New Positions

HolderShares% AssetsChangeValue
Susquehanna group, llp49.09K-49.09K$46.88K
Raymond james & associates38.83K-38.83K$36.79K
Two sigma securities32.13K0.00%32.13K$27.08K
Two sigma advisers, lp29.69K0.00%29.69K$25.02K
Hrt financial lp24.74K0.00%24.74K$20.00K

Sold Out

HolderChange
Qube research-4.00
Jpmorgan chase-62.00
Wells fargo & company/mn-108.00
Royal bank of canada-533.00
Tower research capital llc (trc)-15.41K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2025365.88%22,051,916-1.34%222.55%1110.00%3-72.73%
Jun 30, 2025343.03%23,770,26321.47%314.64%11-21.43%1042.86%
Mar 31, 202535-22,528,206-12.87%301.82%14-6.67%716.67%
Dec 31, 202417-48.48%13,981,677-12.36%223.49%5-64.29%4-
Sep 30, 2024326.67%14,477,82411.08%221.05%14-12.50%4-20.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv723.75K1.40%-15.82K
Vanguard Institutional Extnd Mkt Idx Tr296.87K0.57%-111.64K
Fidelity Extended Market Index186.26K0.36%-1.53K
Fidelity Total Market Index63.59K0.12%-135.00
iShares Micro-Cap ETF59.99K0.12%-
Bridgeway Ultra-Small Company Market56.08K0.11%-15.00K
Fidelity Series Total Market Index50.06K0.10%-
NT Ext Equity Mkt Idx Fd - NL34.73K0.07%-
Spartan Extended Market Index Pool F34.41K0.07%1.53K
Northern Trust Extended Eq Market Idx30.97K0.06%-

Recent Insider Transactions


DateNameRoleActivityValue
Jun 16, 2025Shannon James Samuel-Buy$30.87K
Jun 17, 2025Shannon James Samuel-Buy$17.21K
Jun 16, 2025Russo Rene PRESIDENT AND CEOBuy$24.68K
Jun 05, 2025GILEAD SCIENCES, INC.-Buy$10.00M
Jun 05, 2025GILEAD SCIENCES, INC.-Buy$10.00M

Insider Transactions Trends


DateBuySell
2025 Q27-
2025 Q1-2
2024 Q42-
2024 Q3--
2024 Q22-

XLO Ownership FAQ


Who Owns Xilio Therapeutics?

Xilio Therapeutics shareholders are primarily institutional investors at 22.86%, followed by 45.12% insiders and 32.02% retail investors. The average institutional ownership in Xilio Therapeutics's industry, Biotech Stocks , is 45.22%, which Xilio Therapeutics falls below.

Who owns the most shares of Xilio Therapeutics?

Xilio Therapeutics’s largest shareholders are Gilead sciences (9.11M shares, 9.44%), Rivervest venture management (1.44M shares, 5.16%), and Bain capital life sciences investors (4.57M shares, 4.74%). Together, they hold 19.34% of Xilio Therapeutics’s total shares outstanding.

Does Blackrock own Xilio Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Xilio Therapeutics.

Who is Xilio Therapeutics’s biggest shareholder by percentage of total assets invested?

Rivervest venture management is Xilio Therapeutics’s biggest shareholder by percentage of total assets invested, with 20.01% of its assets in 1.44M Xilio Therapeutics shares, valued at 1.37M$.

Who is the top mutual fund holder of Xilio Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Xilio Therapeutics shares, with 1.40% of its total shares outstanding invested in 723.74K Xilio Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools